PMC:7102591 / 17875-19692
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
557 | 527-537 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
558 | 548-563 | Species | denotes | Betacoronavirus | Tax:694002 |
559 | 602-610 | Species | denotes | SARS-CoV | Tax:694009 |
560 | 615-623 | Species | denotes | MERS-Cov | Tax:1335626 |
561 | 1496-1507 | Species | denotes | coronavirus | Tax:11118 |
562 | 1572-1581 | Species | denotes | SARS-CoV2 | Tax:2697049 |
563 | 1610-1615 | Species | denotes | human | Tax:9606 |
564 | 1454-1459 | Species | denotes | human | Tax:9606 |
565 | 706-715 | Chemical | denotes | ribavirin | MESH:D012254 |
566 | 721-740 | Chemical | denotes | lopinavir-ritonavir | MESH:C558899 |
567 | 836-855 | Chemical | denotes | lopinavir-ritonavir | MESH:C558899 |
568 | 938-948 | Chemical | denotes | remdesivir | MESH:C000606551 |
569 | 953-962 | Chemical | denotes | adenosine | MESH:D000241 |
570 | 1260-1279 | Chemical | denotes | lopinavir-ritonavir | MESH:C558899 |
571 | 1284-1294 | Chemical | denotes | remdesevir | |
572 | 89-104 | Disease | denotes | CoV-2 infection | MESH:C000657245 |
573 | 145-153 | Disease | denotes | COVID-19 | MESH:C000657245 |
574 | 350-358 | Disease | denotes | COVID-19 | MESH:C000657245 |
575 | 459-475 | Disease | denotes | viral infections | MESH:D001102 |
576 | 772-780 | Disease | denotes | COVID-19 | MESH:C000657245 |
577 | 1028-1043 | Disease | denotes | virus infection | MESH:D001102 |
578 | 1219-1239 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
579 | 1392-1400 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T69 | 1139-1142 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T70 | 1623-1628 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T210 | 84-92 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T211 | 95-104 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T212 | 145-153 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T213 | 350-358 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T214 | 459-475 | Disease | denotes | viral infections | http://purl.obolibrary.org/obo/MONDO_0005108 |
T215 | 527-535 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T216 | 602-610 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T217 | 772-780 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T218 | 1022-1027 | Disease | denotes | Ebola | http://purl.obolibrary.org/obo/MONDO_0005737 |
T219 | 1028-1043 | Disease | denotes | virus infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
T220 | 1034-1043 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T221 | 1219-1227 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T222 | 1230-1239 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T223 | 1392-1400 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T224 | 1572-1576 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T127 | 186-187 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T128 | 382-389 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T129 | 1028-1033 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T130 | 1050-1053 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T131 | 1082-1083 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T132 | 1120-1121 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T133 | 1143-1150 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
T134 | 1454-1459 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T135 | 1610-1615 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T136 | 1623-1628 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T134 | 419-434 | Chemical | denotes | antiviral drugs | http://purl.obolibrary.org/obo/CHEBI_36044 |
T135 | 419-428 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T136 | 429-434 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T137 | 634-639 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T138 | 694-704 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T139 | 706-715 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
T140 | 721-740 | Chemical | denotes | lopinavir-ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T141 | 721-730 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T142 | 731-740 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T143 | 836-855 | Chemical | denotes | lopinavir-ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T144 | 836-845 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T145 | 846-855 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T146 | 938-948 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T147 | 953-962 | Chemical | denotes | adenosine | http://purl.obolibrary.org/obo/CHEBI_16335 |
T148 | 1094-1103 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T149 | 1260-1279 | Chemical | denotes | lopinavir-ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T150 | 1260-1269 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T151 | 1270-1279 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T152 | 1329-1334 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T26 | 459-475 | http://purl.obolibrary.org/obo/GO_0016032 | denotes | viral infections |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T95 | 0-287 | Sentence | denotes | Currently, vaccines and approved targeted therapeutics for the treatment of the new SARS-CoV-2 infection are still lacking and the management of COVID-19 is only supportive, even though a multitude of compounds are now under investigation for the treatment of this emerging disease [75]. |
T96 | 288-476 | Sentence | denotes | The need to urgently identify an effective approach to manage COVID-19 led to the strategy of testing the efficacy of the existing antiviral drugs commonly used for other viral infections. |
T97 | 477-786 | Sentence | denotes | In particular, considering the similarity between SARS-CoV-2 and other Betacoronavirus associated with previous epidemics as SARS-CoV and MERS-Cov, the same drugs used with controversial results for these conditions (interferon, ribavirin, and lopinavir-ritonavir) have been considered even for COVID-19 [76]. |
T98 | 787-924 | Sentence | denotes | Anecdotal cases have demonstrated the ability of lopinavir-ritonavir to significantly reduce viral load and improve disease outcome [77]. |
T99 | 925-1245 | Sentence | denotes | In addition, remdesivir, an adenosine analogue currently under development for the management of Ebola virus infection [78], has been recently recognized as a promising antiviral therapy against a wide spectrum of RNA viruses [79] and showed good preliminary in vitro results in the control of SARS-CoV-2 infection [80]. |
T100 | 1246-1406 | Sentence | denotes | Consequently, lopinavir-ritonavir and remdesevir are currently the only anti-viral drugs included in the more severe case management protocols of COVID-19 [10]. |
T101 | 1407-1637 | Sentence | denotes | Recent reports described the potential role of human monoclonal antibodies that bind the coronavirus spike receptor binding domain, leading to the neutralization of SARS-CoV2 capability to interact with human target cells [81,82]. |
T102 | 1638-1817 | Sentence | denotes | However, at the moment these can only be considered as potential treatment options for the future, but they are obviously not available for the management of the current pandemic. |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32205186-26868298-4826910 | 782-784 | 26868298 | denotes | 76 |
32205186-32020029-4826911 | 1241-1243 | 32020029 | denotes | 80 |
32205186-30938227-4826912 | 1630-1632 | 30938227 | denotes | 81 |